Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) (COMRADE-C)
A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Central Retinal Vein Occlusion (CRVO)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Augsburg, Germany, 85155
- Novartis Investigative Site
-
Bad Rothenfelde, Germany, 49215
- Novartis Investigative Site
-
Berlin, Germany, 10713
- Novartis Investigative Site
-
Berlin, Germany, 13353
- Novartis Investigative Site
-
Bonn, Germany, 53127
- Novartis Investigative Site
-
Bremen, Germany, 28209
- Novartis Investigative Site
-
Chemnitz, Germany, 09116
- Novartis Investigative Site
-
Darmstadt, Germany, 64298
- Novartis Investigative Site
-
Dortmund, Germany, 44137
- Novartis Investigative Site
-
Dresden, Germany, 01307
- Novartis Investigative Site
-
Duesseldorf, Germany, 40225
- Novartis Investigative Site
-
Frankfurt, Germany, 60318
- Novartis Investigative Site
-
Freiburg i. Br, Germany, 79106
- Novartis Investigative Site
-
Glauchau, Germany, 08371
- Novartis Investigative Site
-
Göttingen, Germany, 37075
- Novartis Investigative Site
-
Hagen, Germany, 58097
- Novartis Investigative Site
-
Hamburg, Germany, 20246
- Novartis Investigative Site
-
Hamburg, Germany, 22417
- Novartis Investigative Site
-
Homburg, Germany, 66421
- Novartis Investigative Site
-
Ingolstadt, Germany, 85049
- Novartis Investigative Site
-
Karlsruhe, Germany, 76133
- Novartis Investigative Site
-
Karlsruhe, Germany, 76199
- Novartis Investigative Site
-
Kiel, Germany, 24105
- Novartis Investigative Site
-
Koeln, Germany, 50935
- Novartis Investigative Site
-
Lauterbach, Germany, 36341
- Novartis Investigative Site
-
Leipzig, Germany, 04103
- Novartis Investigative Site
-
Ludwigshafen, Germany, 67063
- Novartis Investigative Site
-
Minden, Germany, 32427
- Novartis Investigative Site
-
Muelheim, Germany, 45468
- Novartis Investigative Site
-
Muenster, Germany, 48149
- Novartis Investigative Site
-
Muenster, Germany, 48145
- Novartis Investigative Site
-
München, Germany, 81675
- Novartis Investigative Site
-
München, Germany, 80336
- Novartis Investigative Site
-
Nuernberg, Germany, 90491
- Novartis Investigative Site
-
Recklinghausen, Germany, 45657
- Novartis Investigative Site
-
Regensburg, Germany, 93042
- Novartis Investigative Site
-
Sulzbach, Germany, 66280
- Novartis Investigative Site
-
Tübingen, Germany, 72076
- Novartis Investigative Site
-
Ulm, Germany, 89075
- Novartis Investigative Site
-
Wolfsburg, Germany, 38442
- Novartis Investigative Site
-
Würzburg, Germany, 97080
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungary, 1083
- Novartis Investigative Site
-
Budapest, Hungary, 1133
- Novartis Investigative Site
-
Szeged, Hungary, H-6720
- Novartis Investigative Site
-
-
-
-
-
Bydgoszcz, Poland
- Novartis Investigative Site
-
Bytom, Poland, 41-902
- Novartis Investigative Site
-
-
-
-
-
Birmingham, United Kingdom, B152WB
- Novartis Investigative Site
-
Birmingham, United Kingdom, B18 7QU
- Novartis Investigative Site
-
Bradford, United Kingdom, BD9 6RJ
- Novartis Investigative Site
-
Cheshire, United Kingdom, CW1 4QJ
- Novartis Investigative Site
-
Colchester, United Kingdom, CO3 3NB
- Novartis Investigative Site
-
Derby, United Kingdom, DE22 3NE
- Novartis Investigative Site
-
Gloucester, United Kingdom, GL1 3NN
- Novartis Investigative Site
-
Guildford, Surrey, United Kingdom, GU2 5XX
- Novartis Investigative Site
-
Kent, United Kingdom, CT1 3NG
- Novartis Investigative Site
-
Leeds, United Kingdom, LS9 7TF
- Novartis Investigative Site
-
London, United Kingdom, SE1 7EH
- Novartis Investigative Site
-
Manchester, United Kingdom, M13 9WH
- Novartis Investigative Site
-
Middlesborough, United Kingdom, TS4 3BW
- Novartis Investigative Site
-
Nottingham, United Kingdom, NG7 2UH
- Novartis Investigative Site
-
Portsmouth, United Kingdom, PO6 3LY
- Novartis Investigative Site
-
Rugby, United Kingdom, CV22 5PX
- Novartis Investigative Site
-
Westcliff-on-Sea, United Kingdom, SS0 0RY
- Novartis Investigative Site
-
York, United Kingdom, YO31 8HE
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with visual impairment due to macular edema following CRVO
- Diagnosis of CRVO at maximum 6 months prior to Screening
- BCVA using ETDRS charts of 20/40 to 20/400 in the study eye
Exclusion Criteria:
- Media clarity, pupillary dilation and patient cooperation not sufficient for adequate fundus photographs
- Central retinal thickness (CRT) < 250 µm in the study eye
- Prior episode of RVO in the study eye
- Active formation of new vessels in the study eye
- Anti-VEGF-treatment in the study or the fellow eye 3 months prior to Baseline
- IOP ≥ 30mmHg or uncontrolled glaucoma; patients may be re-screened after 1 month if they have undergone glaucoma treatment
- Improvement of > 10 letters on BCVA between Screening and Baseline
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard of Care
|
|
|
Experimental: Ranibizumab
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Average BCVA Change From Month 1 Through Month 6 to Baseline
Time Frame: Baseline, month 6
|
the average of the changes in BCVA (letters) from baseline to any post-baseline visit, i.e. the mean of six differences to baseline for the six post-baseline visits at month 1 to 6. BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.
An ETDRS visual acuity score of 85 is pproximately 20/20.
An increased score indicates improvement in acuity
|
Baseline, month 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Achieve a Significant Improvement ≥ 15 Letters
Time Frame: Baseline, month 6
|
The time was analyzed by the Kaplan-Maier-Method, adjusting the calculation for dropouts
|
Baseline, month 6
|
|
Change Over Time of the Central Retinal Thickness (CRT)
Time Frame: Baseline, month 6
|
Retinal thickness was measured using Optical Coherence Tomography (OCT).
The images were reviewed by a central reading center to ensure a standardized evaluation
|
Baseline, month 6
|
|
Changes in the Quality of Life According to the Short Form (36) Health Survey (SF-36)Questionnaires
Time Frame: Baseline, month 6
|
SF-36 summary measures are norm-based scores with mean = 50 and SD = 10.
Higher scores indicate better health
|
Baseline, month 6
|
|
Changes in the Quality of Life According to Euro Quality of Life (EQ-5D) Questionnaires
Time Frame: Baseline, month 6
|
The EQ-5D visual analog scale ranges from 0 to 100, 0 representing the worst and 100 the best imaginable health state.
|
Baseline, month 6
|
|
Mean BCVA Change at Month 6
Time Frame: Baseline, month 6
|
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
|
Baseline, month 6
|
|
Number of Patients Gaining / Losing ≥ 15 / 10 / 5 Letters
Time Frame: Baseline, 6 month
|
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters.
An ETDRS visual acuity score of 85 is approximately 20/20.
An increased score indicates improvement in acuity.
This outcome assessed the number of participants who gained 15, 10 or 5 more letters of visual acuity at month 6 as compared with baseline
|
Baseline, 6 month
|
|
Change Over Time in BCVA
Time Frame: Baseline, month 6
|
The analysis was performed by an analysis of covariance (ANCOVA) model with average change in BCVA (letters) from Visit 1 through Visit 6 as dependent variable, and with the factors center, treatment and covariate baseline BCVA as predictors
|
Baseline, month 6
|
|
Changes in the Quality of Life According to the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) Questionnaires
Time Frame: Baseline, month 6
|
The VFQ-25 composite and subscale scores range from 0 to 100, a higher score indicating better functioning.
The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision.
The scores on the subscales were added together for a total score, which ranged from 0 to 100.
A higher score indicated improvement in quality of life due to vision function
|
Baseline, month 6
|
|
Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline
Time Frame: Baseline, month 6
|
The proportion of patients with ≥ 10% increase in Internal Ocular Pressure (IOP) compared to baseline at any post-baseline visit.
|
Baseline, month 6
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Eye Diseases
- Neurologic Manifestations
- Retinal Degeneration
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Macular Degeneration
- Sensation Disorders
- Macular Edema
- Retinal Vein Occlusion
- Edema
- Vision, Low
- Vision Disorders
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Ranibizumab
Other Study ID Numbers
Other Study ID Numbers
- CRFB002EDE18
- 2011-001020-38 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.